Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.

American journal of kidney diseases : the official journal of the National Kidney Foundation - 1 May 2010

Boyer Olivia, Balzamo Eve, Charbit Marina, Biebuyck-Gougé Nathalie, Salomon Rémi, Dragon-Durey Marie-Agnès, Frémeaux-Bacchi Véronique, Niaudet Patrick

Abstract excerpt

We report 3 children with atypical hemolytic uremic syndrome associated with anti-complement factor H (CFH) autoantibodies who presented with sustained remission with low antibody titers and normal kidney function after plasma exchanges (PEs) and cyclophosphamide pulses. The 3 children initially...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to Blood Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement C3b Inactivator Proteins

Share to Complement Factor H

Share to Cyclophosphamide

Share to Enzyme-Linked Immunosorbent Assay

Share to Hemolytic-Uremic Syndrome

Share to Immunosuppressive Agents

Source

Identifiers

PMID: 20202729
DOI: 10.1053/j.ajkd.2009.12.026

Genes

CFH
CFHR1
CFHR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20202729-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.PMID 20202729Read ↗

Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment.Semantic proximity Read ↗

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin.Semantic proximity Read ↗

Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations.Semantic proximity Read ↗

Kidney Transplant Outcomes in Patients with Atypical Hemolytic Uremic Syndrome.Semantic proximity Read ↗

Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.Semantic proximity Read ↗

Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange.Semantic proximity Read ↗

Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysisSemantic proximity Read ↗

Successful kidney transplant with eculizumab, thymoglobulin and belatacept therapy in a highly-sensitised patient with atypical haemolytic uraemic syndrome due to factor H mutation.Semantic proximity Read ↗

Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.Semantic proximity Read ↗

Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.Semantic proximity Read ↗

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.